In the study performed by Ivey et al., using BM and PB of the AML patients, the presence of NPM1-mutated transcripts after the second chemotherapy cycle was associated with a significantly higher relapse risk and poorer survival rates, independent of other known prognostic factors [127]. The gene discussed is NPM1; the disease is acute myeloid leukemia.